ALGEN Fundamental Analysis - GENOWAY SA

Fundamental Rating

ALGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGEN was profitable.

ALGEN had a positive operating cash flow in the past year.

In multiple years ALGEN reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of 3.96%, ALGEN is in the better half of the industry, outperforming 74.67% of the companies in the same industry.

ALGEN has a better Return On Equity (7.06%) than 76.00% of its industry peers.

ALGEN's Return On Invested Capital of 6.13% is amongst the best of the industry. ALGEN outperforms 82.67% of its industry peers.

ALGEN had an Average Return On Invested Capital over the past 3 years of 5.56%. This is significantly below the industry average of 13.78%.

The 3 year average ROIC (5.56%) for ALGEN is below the current ROIC(6.13%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROIC	6.13%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

1.3 Margins

ALGEN has a better Profit Margin (5.86%) than 74.67% of its industry peers.

Looking at the Operating Margin, with a value of 8.09%, ALGEN is in the better half of the industry, outperforming 77.33% of the companies in the same industry.

ALGEN has a better Gross Margin (92.34%) than 86.67% of its industry peers.

ALGEN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	8.09%
PM (TTM)	5.86%
GM	92.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.

ALGEN has less shares outstanding than it did 1 year ago.

The number of shares outstanding for ALGEN has been increased compared to 5 years ago.

ALGEN has a better debt/assets ratio than last year.

2.2 Solvency

ALGEN has an Altman-Z score of 2.37. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.

ALGEN has a Altman-Z score of 2.37. This is in the better half of the industry: ALGEN outperforms 68.00% of its industry peers.

The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.

With an excellent Debt to FCF ratio value of 1.41, ALGEN belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.

A Debt/Equity ratio of 0.26 indicates that ALGEN is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.26, ALGEN is in line with its industry, outperforming 56.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Altman-Z	2.37

ROIC/WACC0.89

WACC6.92%

2.3 Liquidity

ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of ALGEN (1.92) is comparable to the rest of the industry.

ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of ALGEN (1.81) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.92
Quick Ratio	1.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.41% over the past year.

The Revenue has grown by 10.04% in the past year. This is quite good.

Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.46% on average per year.

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

3.2 Future

Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.

ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGEN is valuated correctly with a Price/Earnings ratio of 13.24.

Based on the Price/Earnings ratio, ALGEN is valued cheaper than 88.00% of the companies in the same industry.

When comparing the Price/Earnings ratio of ALGEN to the average of the S&P500 Index (27.20), we can say ALGEN is valued rather cheaply.

		Industry Rank	Sector Rank
PE	13.24
Fwd PE	N/A

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 92.00% of the companies in the same industry.

ALGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALGEN is cheaper than 93.33% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	5.82
EV/EBITDA	4.6

4.3 Compensation for Growth

ALGEN has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.42%

EPS Next 3Y0%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENOWAY SA

EPA:ALGEN (9/17/2025, 7:00:00 PM)

2.78

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners5.68%

Inst Owner ChangeN/A

Ins Owners9.39%

Ins Owner ChangeN/A

Market Cap26.35M

Analysts86.67

Price Target6.02 (116.55%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	13.24
Fwd PE	N/A
P/S	1.23
P/FCF	5.82
P/OCF	3.81
P/B	1.48
P/tB	2.17
EV/EBITDA	4.6

EPS(TTM)0.21

EY7.55%

EPS(NY)0

Fwd EYN/A

FCF(TTM)0.48

FCFY17.19%

OCF(TTM)0.73

OCFY26.21%

SpS2.26

BVpS1.88

TBVpS1.28

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROCE	7.62%
ROIC	6.13%
ROICexc	7.79%
ROICexgc	11.35%
OM	8.09%
PM (TTM)	5.86%
GM	92.34%
FCFM	21.15%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

ROICexc(3y)6.94%

ROICexc(5y)N/A

ROICexgc(3y)9.99%

ROICexgc(5y)N/A

ROCE(3y)6.91%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

F-Score5

Asset Turnover0.68

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Debt/EBITDA	0.77
Cap/Depr	55.06%
Cap/Sales	11.1%
Interest Coverage	250
Cash Conversion	114.18%
Profit Quality	360.76%
Current Ratio	1.92
Quick Ratio	1.81
Altman-Z	2.37

F-Score5

WACC6.92%

ROIC/WACC0.89

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

EBIT growth 1Y0.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year200%

EBIT Next 3Y68.69%

EBIT Next 5YN/A

FCF growth 1Y308.02%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y1010.09%

OCF growth 3YN/A

OCF growth 5YN/A

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens